By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Syntonix Pharmaceuticals, Inc. 

9 Fourth Avenue

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-547-6000 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
Zenobia Therapeutics, Inc. Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals, Inc. 4/14/2009 9:10:51 AM
Biovitrum AB's and Syntonix Pharmaceuticals, Inc.'s Novel Factor IXFc for Hemophilia B has Received Orphan Drug Designation From the FDA 11/24/2008 10:09:24 AM
Biovitrum AB and Syntonix Pharmaceuticals, Inc. Dose First Hemophilia B Patient in Clinical Trial of a Novel Factor IXFc Treatment 5/27/2008 2:40:37 PM
Biovitrum AB and Syntonix Pharmaceuticals, Inc. Dose First Hemophilia B Patient in Clinical Trial of a Novel Factor IXFc Treatment 5/27/2008 9:26:21 AM
Biovitrum AB and Syntonix Pharmaceuticals, Inc. Set to Begin Phase I/IIa Clinical Trial 3/4/2008 7:08:50 AM
The Day In Review: Schering-Plough Corporation (SGP) Gets Approval For Noxafil 9/18/2006 5:11:23 PM
Serono International S.A. (SRA) And Syntonix Pharmaceuticals, Inc. To Pursue The Development Of A Long-Acting, Inhaleable FSH Therapy To Treat Infertility 9/18/2006 1:07:18 PM
Biovitrum AB And Syntonix Pharmaceuticals, Inc. Enter Agreement For The Joint Development And Commercialization Of Recombinant Factor IX For The Treatment Of Hemophilia 1/23/2006 11:41:22 AM
Syntonix Pharmaceuticals, Inc. And Boehringer Ingelheim Corporation Enter Collaboration For Up To $63 Million To Optimize Therapeutic 10/21/2005 11:02:55 AM
Serono International S.A. (SRA) And Syntonix Pharmaceuticals, Inc. Sign Worldwide Agreement To Develop And Commercialize An Inhaleable Interferon-Beta Therapy For Multiple Sclerosis10/19/2005 5:13:10 PM
12
//-->